

**WYDUR Board Meeting Minutes**  
**Thursday, March 30, 2006**  
Hampton Inn, Laramie, Wyoming  
11a.m.-3p.m.

Members Present: Steve Brown, Mike Carpenter, Becky Drnas, Bill Harrison, Kurt Hopfensperger, Richard Johnston, James Robinett, Dean Winsch, Antoinette Brown, Roxanne Homar, Aimee Lewis, Linda Martin, Laura Miller

Members Excused: Bill Keenan, Scott Johnston

By Teleconference: Deb Devereaux, Kendra Grande

Guests: Jennifer Stoll (Sepracor), Terri Craig (Pfizer), Carmen Pyper (Pfizer), Jared Buehler (Pfizer), Marilyn Wright (GSK), Justin French (Sepracor), John Stockton (Genentech), Troy Lessman (Pharmacy Intern), Jeff Jenkins (Merck), Joan Solem (Lilly)

The meeting was called to order by Chair, Bill Harrison. The members and guests were introduced. Becky Drnas was elected without opposition to the Vice Chair position on the DUR Board. Dr. Melinkovich will be leaving the Department of Health to serve as the Medical Director for BCBS in Wyoming.

The minutes of the January 26, 2006 meeting were approved as presented.

Department of Health

- A. Part D-Transition supplies are ending. SPAP transition will be in April and will affect about 500 patients. The benefit under Part D is more comprehensive for those patients. There are significant B vs. D issues (B12 injection, Folic Acid tablets). The Department of Health will wrap around these items beginning in April.
- B. Legislative update-Budget presentation went well. The DOH is waiting for specific line by line amounts. The budget request for the biennium is \$1.4 billion. A bill which would allow pharmacists to immunize healthy adults without a prescription (influenza and pneumovax) was approved. With a prescription, children and adults with travelers' immunizations can be inoculated. Vital signs, epinephrine availability etc. will be part of guidelines from the Board of Pharmacy. Notice will be faxed to physician's offices. There will be a training program that pharmacists must participate in.
- C. PA Statistics (see handout)
- D. Other-LTC returns policy implemented Fall '03 although NCPDP 5.1 can't accurately process because it shows up as a fall claim
- E. PDLAC meeting is April 12 in Cheyenne. Pediatric participation in the PA program will be discussed.
- F. ACE vs. ARBS: the necessity of starting with an ACEI before trying an ARB will be proposed as criteria at the next DUR meeting
- G. Dept of Health will be adding PDL formulary to e-Pocrates.

New Business

- A. APS Presentation postponed. Megan Cormier is the new director. They would like to present a full years (2005) data which Milleman has verified. The previously reported

\$15 million was actually cost avoidances rather than cost savings. The Board approved the sending of a letter regarding the lack of data and timeliness of reporting. Discussions will also be introduced at the Physician Advisory Group and the Medical Society Board.

B. Criteria

1. Celebrex/NSAIDs revised criteria approved. April 20, 2006 effective date.
  2. Actiq criteria revised as noted. Final copy will be sent to Board. Discussion regarding limiting prescribing to certain physicians. Can't do in Wyoming.
  3. Xopenex-implementation postponed due to shortage of short acting bronchodilators in the market and concerns about therapeutic alternatives and safety issues. Estimated implementation may be July 1. Criteria approved.
  4. Xolair-criteria approved. Will be in the Smart PA system.
- C. Pregabalin study-64 recipients currently utilizing. Are patients being switched from gabapentin to pregabalin? Anticonvulsants proposed criteria and strategy will be discussed at the next meeting.

Old Business

- A. MS Project-Dr. Hopfensperger will be giving the live CME presentation. Two hundred nineteen patients and one hundred twenty four providers will be sent the letters and educational materials.
- B. MH Project-we found 1800 prescribers. The Board discussed the information. Follow-up questions are: What percent of the total prescriptions are being written by psych ANPs, Psychiatrists and psych PAs? How many patients are taking more than 2, 3, or 4 atypical antipsychotics? For what ICDs are medications being prescribed and the number of different medications?

Kendra will investigate Lexapro vs. Celexa and the data to justify use of Lexapro. Kendra will also review article noted in WSJ about multiple antidepressants needed to treat patients to remission.

The DUR Board recommended that the Department of Health move toward a Preferred Drug List for SSRI medications because there are so many generic options available. There was also some discussion about the effectiveness of EEG Brain mapping and the resources diverted to reimbursement of that procedure. Roxanne will follow up.

There were no open comments. There were not alert changes. There being no further business, the meeting was adjourned at 3p.m.

Respectfully Submitted,

Debra S. Devereaux MBA, R.Ph.  
Wyoming DUR Manager